<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lazzerini PE</submitter><funding>BLRD VA</funding><funding>NHLBI NIH HHS</funding><pagination>e032071</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11010073</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(4)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Although accumulating data indicate that IL-6 (interleukin-6) can promote heart rate-corrected QT interval (QTc) prolongation via direct and indirect effects on cardiac electrophysiology, current evidence comes from basic investigations and small clinical studies only. Therefore, IL-6 is still largely ignored in the clinical management of long-QT syndrome and related arrhythmias. The aim of this study was to estimate the risk of QTc prolongation associated with elevated IL-6 levels in a large population of unselected subjects.&lt;h4>Methods and results&lt;/h4>An observational study using the Veterans Affairs Informatics and Computing Infrastructure was performed. Participants were US veterans who had an ECG and were tested for IL-6. Descriptive statistics and univariate and mu</pubmed_abstract><journal>Journal of the American Heart Association</journal><pubmed_title>Elevated Interleukin-6 Levels Are Associated With an Increased Risk of QTc Interval Prolongation in a Large Cohort of US Veterans.</pubmed_title><pmcid>PMC11010073</pmcid><funding_grant_id>I01 BX002137</funding_grant_id><funding_grant_id>R01 HL164415</funding_grant_id><pubmed_authors>Acampa M</pubmed_authors><pubmed_authors>Salvadori F</pubmed_authors><pubmed_authors>Cupelli M</pubmed_authors><pubmed_authors>Cevenini G</pubmed_authors><pubmed_authors>Marzotti T</pubmed_authors><pubmed_authors>Bisogno S</pubmed_authors><pubmed_authors>Accioli R</pubmed_authors><pubmed_authors>Cartocci A</pubmed_authors><pubmed_authors>Capecchi PL</pubmed_authors><pubmed_authors>El-Sherif N</pubmed_authors><pubmed_authors>Boutjdir M</pubmed_authors><pubmed_authors>Salvini V</pubmed_authors><pubmed_authors>Bernardini S</pubmed_authors><pubmed_authors>Lazzerini PE</pubmed_authors><pubmed_authors>Bicchi M</pubmed_authors><pubmed_authors>Laghi-Pasini F</pubmed_authors><pubmed_authors>Bertolozzi I</pubmed_authors><pubmed_authors>Verrengia D</pubmed_authors><pubmed_authors>Donati G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Elevated Interleukin-6 Levels Are Associated With an Increased Risk of QTc Interval Prolongation in a Large Cohort of US Veterans.</name><description>&lt;h4>Background&lt;/h4>Although accumulating data indicate that IL-6 (interleukin-6) can promote heart rate-corrected QT interval (QTc) prolongation via direct and indirect effects on cardiac electrophysiology, current evidence comes from basic investigations and small clinical studies only. Therefore, IL-6 is still largely ignored in the clinical management of long-QT syndrome and related arrhythmias. The aim of this study was to estimate the risk of QTc prolongation associated with elevated IL-6 levels in a large population of unselected subjects.&lt;h4>Methods and results&lt;/h4>An observational study using the Veterans Affairs Informatics and Computing Infrastructure was performed. Participants were US veterans who had an ECG and were tested for IL-6. Descriptive statistics and univariate and mu</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Feb</publication><modification>2025-04-26T20:11:11.894Z</modification><creation>2025-04-06T16:19:49.213Z</creation></dates><accession>S-EPMC11010073</accession><cross_references><pubmed>38348789</pubmed><doi>10.1161/JAHA.123.032071</doi></cross_references></HashMap>